• 제목/요약/키워드: Cytosine arabinoside

검색결과 23건 처리시간 0.018초

백혈병 세포주에 대한 $(\pm)$-ar-Turmerone, 자근 및 황금추출물에 의한 항암제의 세포독성 증강효과 (Augmentation of the Cytotoxic Effects of Anticancer Drugs by $(\pm)$-ar-Turmerone and Extracts of the Lithosperma and Scutellaria Roots against Human Leukemia Cell Lines)

  • 이윤영;유관희;김삼용;안병준
    • 약학회지
    • /
    • 제35권3호
    • /
    • pp.203-215
    • /
    • 1991
  • Using the calorimetric [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] (MTT)assay, we evaluated the chemosensitivity of 8 anticancer drugs{vincristine(VCR), vinblastine(VBL), adriamycin(ADR), cisplatin(CPDD), etoposide(VP-16), cytosine arabinoside(ara-C), bleomycin (Bleo) and cyclophosphamide(CYC)} and the cytotoxicity-enhancing effects of ($\pm$)-ar-turmerone and the extracts of the crude drugs {Lithospermum eythrorhizon(LE) and Scutellaria baicalensis (SB)} on the above mentioned anticancer drugs against HL-60 and KG-1 cells among 8 anticancer drugs, VCR, VBL, ADR, and CPDD inhibited the growth of both cell lines by more than 50%, while VP-16, ara-C, Bleo, and CYC were less effective. ($\pm$)-ar-Turmerone had significant inhibitory effects against both cell lines, showing the ID$_{50}$ values of 11.730 $\mu\textrm{g}$/ml and 0.292 $\mu\textrm{g}$/ml for HL-60 and KG-1 cells. respectively. But the extracts of LE and SB roots showed no significant cytotoxic effects. According to ID$_{50}$ values, the cytotoxicities of VCR, VBL and ADR against HL-60 were enhanced two, eight and three times by mixing ($\pm$)-ar-turmerone, five, seven and three times by adding the extract of LE root, and twenty, six and three times by mixing the extract of SB root, respectively. The cytotoxicities of the above mentioned drugs against KG-1 cell were enhanced two, seven and three times by mixing ($\pm$)-ar-turmerone, two, three and three times by combining wilth the extract of LB root, and two, five and two times by adding the extract of SB root, respectively. The cytotoxicity-potentiating effects of ($\pm$)-ar-turmerone and the extracts of LE and SB roots against HL-60 cell were greater than KG-1 cell.

  • PDF

Fotemustine, Teniposide and Dexamethasone in Treating Patients with CNS Lymphoma

  • Wu, Jing-Jing;Wang, Xin-Hua;Li, Ling;Li, Xin;Zhang, Lei;Sun, Zhen-Chang;Fu, Xiao-Rui;Ma, Wang;Chang, Yu;Zhang, Xu-Dong;Han, Li-Juan;Zhang, Ming-Zhi
    • Asian Pacific Journal of Cancer Prevention
    • /
    • 제15권11호
    • /
    • pp.4733-4738
    • /
    • 2014
  • Purpose: We developed and evaluated a regimen including fotemustine, teniposide and dexamethasone (FTD) for treating patients with central nervous system (CNS) lymphoma based on pharmacokinetic properties of individual agents and in combination. Patients and Methods: In a comparison study, 8 patients with primary CNS lymphoma (PCNSL) and 8 with secondary CNS lymphoma (SCNSL) were treated with FTD (comprising fotemustine 100 mg/m2, 1h infusion, day 1; teniposide 60 mg/m2, >0.5 h infusion, on day 2, 3, 4; dexamethasone 40 mg, 1h infusion, on day 1, 2, 3, 4 and 5; and methotrexate 12 mg, cytosine arabinoside 50 mg plus dexamethasone 5 mg intrathecally, on day 2 and 7). Cycles were repeated every 3 weeks. After response assessment, patients received whole brain radiotherapy. Results: Of the 8 PCNSL patients, 4 (50%) achieved CR and 3 (38%) PR, an overall response rate of 88%. Four patients (50%) were in continuing remission at the end of this study after a median follow-up of 30 months (range 10 to 56 months). Of the 8 SCNSL patients the overall response rate was 63% (CR+PR: 38%+25%). All responses were achievable with predictable toxicity mainly reflecting reversible myelosuppression. Conclusion: This study suggests that FTD could be an effective treatment for CNS lymphoma, and is worthy of further evaluation.

폐암 세포에서 Gemcitabine에 의한 세포 사멸과 p53의 역할 (Gemcitabine-induced Cell Death in Lung Cancer Cells : the Role of p53)

  • 김도형;배강우;용화심;최은경;김윤섭;박재석;지영구;이계영
    • Tuberculosis and Respiratory Diseases
    • /
    • 제53권3호
    • /
    • pp.275-284
    • /
    • 2002
  • 연구배경: Gemcitabine은 폐암에서 임상적 유용성이 큰 새로운 항암제이다. 저자들은 폐암세포에서 Gemcita bine에 의한 세포 사멸과 p53의 역할을 규명하고자 하였다. 방 법 : 폐암 세포주로 A549와 H358 세포주를 이용하였고 세포 독성 검사는 MTT assay를 이용하였으며 Gemcitabine 농도는 10nM, 100nM, 1uM, 10uM, 100uM을 사용하였다. 세포 주기 검사는 FACScan을 이용하여 분석하였고 p53 활성화 여부는 western blot을 사용하였다. p53 단백질 분해를 촉진시키는 안정적 세포주 A549-E6과 H358-E6을 제조하고 대조 세포주 A549-neo와 H358-neo 세포주와 비교하여 p53의 기능적 knock-out 실험을 시행하였다. p53의 기능적 knock-out은 p53 유도 약제인 doxorubicine 1 M을 사용하여 western blot으로 확인하였다. 결 과 : A549와 H358 세포주에서 Gemcitabine은 농도에 비례한 세포 독성을 보였고 S phase arrest와 p53의 활성화를 유도하였다. 안정적 세포주 A549-E6과 H358-E6은 MTT assay에서 대조 세포주 A549-noo와 H358-noo에 비해 각각 20-30%, 30-40%의 세포 독성 차단효과를 보였다. 결 론 : Gemcitabine은 S phase arrest를 유발시키고 p53 단백질의 활성화를 유도하며 p53의 기능소실이 Gemcitabine에 대한 저항인자로 작용하고 있음을 확인할 수 있었다. 향후 Gemcitabine에 의해 p53의 활성화가 발생하는 신호경로와 p53 활성화에 의한 아포프토시스의 신호경로에 대한 연구가 필요할 것으로 사료된다.